Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

BACKGROUND: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. OBJECTIVES: To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. METHODS: In this retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauma, Ilkka, Mustonen, Tiina, Seppä, Juha Matti, Ukkonen, Maritta, Männikkö, Marianne, Verkkoniemi-Ahola, Auli, Kartau, Marge, Saarinen, Jukka T., Luostarinen, Liisa, Simula, Sakari, Ryytty, Mervi, Ahmasalo, Riitta, Sipilä, Jussi O. T., Pieninkeroinen, Ilkka, Tapiola, Tero, Remes, Anne M., Kuusisto, Hanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782800/
https://www.ncbi.nlm.nih.gov/pubmed/34255182
http://dx.doi.org/10.1007/s00415-021-10664-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782800/
https://www.ncbi.nlm.nih.gov/pubmed/34255182
http://dx.doi.org/10.1007/s00415-021-10664-w

Ejemplares similares